Metastatic and sentinel lymph node mapping using intravenously delivered Panitumumab-IRDye800CW

• Published in: Theranostics Vol. 11; no. 15; pp. 7188 - 7198
• Main Authors: Krishnan, Giri, van den Berg, Nynke S, Nishio, Naoki, Juniper, Georgina, Pei, Jaqueline, Zhou, Quan, Lu, Guolan, Lee, Yu-Jin, Ramos, Kimberly, Iagaru, Andrei H, Baik, Fred M, Colevas, Alexander D, Martin, Brock A, Rosenthal, Eben L
• Format: Journal Article
• Language: English
• Published: Australia Ivyspring International Publisher Pty Ltd 01.01.2021; Ivyspring International Publisher
• Subjects: Administration, Intravenous; Aged; Antibodies; Benzenesulfonates - administration & dosage; Biopsy; Cameras; Dissection; Female; Gamma rays; Head & neck cancer; Head and Neck Neoplasms - pathology; Humans; Indoles - administration & dosage; Lymphatic Metastasis - pathology; Lymphatic system; Male; Metastasis; Middle Aged; Morbidity; Oral cancer; Panitumumab - administration & dosage; Research Paper; Sentinel Lymph Node Biopsy; Squamous cell carcinoma; Squamous Cell Carcinoma of Head and Neck - pathology; Statistical analysis; Surgery; United States > US; Translational science; Head and neck cancer; sentinel lymph node biopsy; Oral squamous cell carcinoma; Fluorescent molecular imaging
• ISSN: 1838-7640; 1838-7640
• DOI: 10.7150/thno.55389

Sentinel lymph node biopsy (SLNB) is a well-established minimally invasive staging procedure that maps the spread of tumour metastases from their primary site to the regional lymphatics. Currently, the procedure requires the local peri-tumoural injection of radiolabelled and/or optical agents, and is therefore operator dependent, disruptive to surgical workflow and restricted largely to a small subset of malignancies that can be readily accessed externally for local tracer injection. The present study set out to determine whether intravenous (IV) infusion of a tumor-targeted tracer could identify sentinel and metastatic lymph nodes (LNs) in order to overcome these limitations. We examined 27 patients with oral squamous cell carcinoma (OSCC), 18 of whom were clinically node negative (cN0). Patients were infused intravenously with 50mg of Panitumumab-IRDye800CW prior to surgical resection of their primary tumour with neck dissection and/or SLNB. Lymphadenectomy specimens underwent fluorescence molecular imaging to evaluate tracer distribution to LNs. A total of 960 LNs were analysed, of which 34 (3.5%) contained metastatic disease. Panitumumab-IRDye800CW preferentially localized to metastatic and sentinel LNs as evidenced by a higher fluorescent signal relative to other lymph nodes. The median MFI of metastatic LNs was significantly higher than the median MFI of benign LNs (0.06 versus 0.02, p < 0.05). Furthermore, selecting the highest five fluorescence intensity LNs from individual specimens resulted in 100% sensitivity, 85.8% specificity and 100% negative predictive value (NPV) for the detection of occult metastases and 100% accuracy for clinically staging the neck. In the cN+ cohort, assessment of the highest 5 fluorescence LNs per patient had 87.5% sensitivity, 93.2% specificity and 99.1% NPV for the detection of metastatic nodes. When intravenously infused, a tumour-targeted tracer localized to sentinel and metastatic lymph nodes. Further validation of an IV tumor-targeted tracer delivery approach for SLNB could dramatically change the practice of SLNB, allowing its application to other malignancies where the primary tumour is not accessible for local tracer injection.